Review anchor
Dual specificity tyrosine-phosphorylation-regulated kinase 3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Dual specificity tyrosine-phosphorylation-regulated kinase 3
CHEMBL4575
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Dual specificity tyrosine-phosphorylation-regulated kinase 3 as ChEMBL target CHEMBL4575, mapped to UniProt O43781. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4575
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O43781
Dual specificity tyrosine-phosphorylation-regulated kinase 3
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Dual specificity tyrosine-phosphorylation-regulated kinase 3 matters
Dual specificity tyrosine-phosphorylation-regulated kinase 3 is reviewed as Dual specificity tyrosine-phosphorylation-regulated kinase 3 (UniProt O43781); the current evidence base includes 4 approved drugs, 1241 compounds, and 227 assays, with lead potency reaching pChEMBL 10.0.
Protein context
Dual specificity tyrosine-phosphorylation-regulated kinase 3
Dual specificity tyrosine-phosphorylation-regulated kinase 3 Sequence length is 588 aa.
Review this target as Dual specificity tyrosine-phosphorylation-regulated kinase 3, mapped to UniProt O43781. Sequence length is 588 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt O43781
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 4 approved drugs, 1241 compounds, and 227 assays for this target. The dominant activity type is KI. CHEMBL4546504 is the current potency anchor at pChEMBL 10.0.
Use CHEMBL4546504 as the tractability anchor when discussing potency (pChEMBL 10.0).
Activity source · ChEMBL 36 via Core Engine
4 approved
pChEMBL 10.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Dual specificity tyrosine-phosphorylation-regulated kinase 3 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt O43781, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1241
Total Compounds
227
Total Assays
4
Approved Drugs
IC50: 487.0, KI: 533.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4546504
|
10.0 | IC50 | — |
|
|
No preferred name
CHEMBL3728543
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL3728359
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL5422486
|
8.7 | IC50 | — |
|
|
No preferred name
CHEMBL1986943
|
8.3 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ABEMACICLIB
CHEMBL3301610
|
2017 |
Source Header